Shareholders of Piramal Pharma approved critical governance and capital structure resolutions at its 6th Annual General Meeting (AGM) held on July 30, 2026. The most significant outcome was the authorization to issue Non-Convertible Debentures (NCDs) on a private placement basis, alongside enabling the creation of pledges over the shareholding in material subsidiaries. These approvals provide the company with flexibility for future debt financing and asset-backed lending structures. The meeting also saw the re-appointment of several key directors, including Chairperson Nandini Piramal and Executive Director Peter DeYoung, ensuring continuity in leadership.

The AGM was conducted through Video Conferencing or Other Audio Visual Means (VC/OAVM), adhering to Ministry of Corporate Affairs (MCA) circulars. Remote e-voting commenced on July 27, 2026, at 9:00 a.m. and concluded on July 29, 2026, at 5:00 p.m., with additional voting available during the live session. The voting rights were reckoned based on shareholding as of July 23, 2026. Bhaskar Upadhyay of N L Bhatia & Associates served as the scrutinizer, confirming that all resolutions passed with the requisite majority under Section 108 of the Companies Act, 2013, and Regulation 44 of the SEBI Listing Regulations, 2015.

Board Re-appointments and Governance

The shareholders re-appointed Peter DeYoung as Whole-Time Director, designated as Executive Director, and Nandini Piramal as Whole-Time Director, designated as Executive Director and Chairperson. Independent Directors Sridhar Gorthi and Peter Stevenson were also re-appointed. Nathalie Leitch was re-appointed as a director retiring by rotation. The ratification of remuneration payable to Cost Auditors for FY2026-27 was also approved as an ordinary resolution.

Voting Results Overview

All ten resolutions were passed successfully. The table below summarizes the voting outcomes for key special resolutions:

Analytical Observation: Institutional Voting Patterns

A review of the voting data reveals a distinct divergence between promoter and institutional investor behavior on specific governance issues. While the promoter group voted unanimously (100%) in favor of all resolutions, public institutional investors showed notable dissent on the re-appointment of certain directors. For instance, approximately 27.15% of votes polled from public institutions were cast against the re-appointment of Peter DeYoung, and 34.96% voted against the re-appointment of Nandini Piramal. Similarly, 31.03% of institutional votes opposed the re-appointment of Sridhar Gorthi. Despite this dissent, the strong support from promoters and non-institutional public shareholders ensured all resolutions passed comfortably. This pattern suggests active engagement by institutional investors on governance matters, even if it did not alter the final outcome.

Piramal Pharma reported a significant improvement in operating performance for the quarter ended June 30, 2026, with consolidated revenue from operations rising 17% to ₹2,270 crore. The group’s EBITDA surged 72% year-on-year to ₹285 crore, expanding margins to 12.5% from 8.5% in Q1FY26, driven by operational leverage across its Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and Piramal Consumer Healthcare (PCH) businesses. Despite the strong top-line and operating profit growth, the consolidated net loss narrowed to ₹69 crore from ₹102 crore before exceptional items in the prior year, as high depreciation and interest costs continued to weigh on the bottom line.

The Board of Directors approved the unaudited financial results on July 29, 2026, in compliance with Regulation 33 of the SEBI Listing Regulations. Statutory auditors Suresh Surana & Associates LLP conducted a limited review of the standalone and consolidated results. The company operates in a single segment, and no exceptional items were recorded during the current quarter, contrasting with Q1FY26 which included a one-time insolvency gain of ₹21 crore.

Financial Performance Overview

Standalone revenue from operations rose to ₹1,124.95 crore from ₹969.88 crore in Q1FY26. Standalone net profit remained flat at ₹113.48 crore compared to ₹113.14 crore in the prior year. On a consolidated basis, total income increased 18% to ₹2,359 crore, supported by other income of ₹89 crore. Total expenses stood at ₹2,386 crore, with material costs rising 23% to ₹852 crore and employee benefits increasing 9% to ₹676 crore. Depreciation expenses climbed 13% to ₹224 crore, while interest expenses remained stable at ₹88 crore.

The table below summarises the key consolidated financial metrics for the quarter:

Segment-Wise Growth Drivers

All three business verticals contributed to the top-line expansion. The CDMO segment led the charge with a 19% revenue increase to ₹1,187 crore, fueled by healthy order inflows, improved utilization across India and overseas sites, and an enhanced commercial team. CHG revenue grew 17% to ₹743 crore, maintaining market leadership in US inhalation anesthesia (Sevoflurane) with a 48% value share and intrathecal therapy. PCH revenue rose 15% to ₹347 crore, driven by 23% growth in Power Brands and 40% expansion in e-commerce sales.

What the Numbers Show

The substantial divergence between EBITDA growth (72%) and net loss reduction highlights the impact of fixed cost structures on bottom-line profitability. While operating leverage successfully expanded margins by 400 basis points, high depreciation (₹224 crore) and interest costs (₹88 crore) continue to pressure net earnings. The absence of exceptional items in Q1FY27 provides a clearer view of operational performance, indicating that the core business is generating stronger cash flows despite the reported net loss. The sustained contribution from associates (₹20 crore share of profit) further supports the group's overall financial stability.